ArticleJournal of neuro-oncology2025
Perovskite nanocrystal probes for intraoperative in vitro pathological detection of IDH1 mutation status in glioma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-generation CsPbBrRSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to construct a perovskite quantum dot probe targeting isocitrate dehydrogenase 1 (IDH1) mutation. The probe is intended to enable rapid in vitro pathological diagnosis of IDH1-mutant glioma, guide surgeons in formulating scientific and rational resection strategies during surgery, and facilitate precise individualized intraoperative treatment for glioma patients.
methodsVia surface ligand engineering, a perovskite nanocrystal (PNC) probe modified with bromobutyric acid (BBA) was developed in this study. This probe enhances water/oxygen stability and addresses the limitation that restricts the application of perovskite quantum dots as fluorescent probes. The probe was used to stain intraoperative tumor frozen sections to verify its specific recognition capability for IDH1-mutant glioma.
resultsVerification using 50 glioma frozen sections demonstrated that the probe could accomplish rapid pathological detection within 30 min (with a 5-minute incubation period). Fluorescence imaging showed specific green fluorescence in IDH1-mutant glioma. When compared with genetic testing results, the probe exhibited the following detection performance: sensitivity of 100%, specificity of 84%, positive predictive value of 86.2%, negative predictive value of 100%, and accuracy of 92% (κ = 0.84, P < 0.001).
conclusionsThis BBA-stabilized perovskite probe enables rapid and specific in vitro detection of IDH1-mutant glioma. It provides real-time guidance for glioma surgery, is expected to assist surgeons in achieving precise resection of glioma, and thus advances the development of precision neuro-oncology.
Indexed as
Identifiers
41359079What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.